ropinirole: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ropinirole: clinical details
Prescribing considerations
- Assess history of psychosis, mania, compulsive behaviour, cardiovascular disease and daytime sleepiness.
- Counsel patients and carers about impulse-control disorders, hallucinations, sudden sleep onset and withdrawal symptoms.
- Review concomitant levodopa if dyskinesia emerges.
- Starting or stopping smoking may alter CYP1A2 metabolism and warrants clinical review.
- Avoid abrupt withdrawal; monitor closely during tapering.
- Rapid gastrointestinal transit may cause incomplete release and visible tablet residue in stools.
Contraindications and cautions
- Hypersensitivity to ropinirole or product excipients.
- Severe renal impairment without regular haemodialysis.
- Hepatic impairment.
Monitoring
- Clinical response and tolerability.
- Blood pressure, especially initially in severe cardiovascular disease.
- Sleepiness, sudden sleep episodes and driving risk.
- Impulse-control disorders, mania, hallucinations and psychotic symptoms.
- Dyskinesia when combined with levodopa.
- Withdrawal symptoms during reduction or discontinuation.
Clinical pharmacology
Ropinirole is a non-ergoline D2/D3 receptor agonist, primarily metabolised by CYP1A2. Protein binding is low, metabolites are mainly excreted in urine, and the principal metabolite has little dopaminergic activity.
Formulation and product differences
- The selected tablets use prolonged release and must remain intact.
- Immediate-release and prolonged-release products are not automatically interchangeable without a planned conversion.
- The selected prolonged-release product is licensed for Parkinson’s disease; indications differ between ropinirole products.
- The tablets contain lactose; one tablet strength also contains sunset yellow, which can cause allergic reactions.
ropinirole interactions
Check prescribed, pharmacy and complementary medicines with a pharmacist or prescriber. Important examples include:
Metoclopramide, sulpiride and other dopamine antagonists
They may oppose ropinirole’s dopamine effect and reduce symptom control.
Ciprofloxacin, fluvoxamine and other CYP1A2 inhibitors
They can increase ropinirole exposure and the likelihood of adverse effects.
High-dose oestrogens, including some HRT
Starting or stopping treatment can alter ropinirole concentrations and may require clinical review.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.